San Diego, CA, United States of America

Juan E Moyron-Quiroz

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Biolegend, Inc.. Active years: 2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Juan E Moyron-Quiroz. Retrieved from https://idiyas.com/inventor/juan-e-moyron-quiroz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Juan E Moyron-Quiroz: Innovator in Anti-Tetraspanin Research

Introduction

Juan E Moyron-Quiroz is a prominent inventor based in San Diego, California. He has made significant contributions to the field of biotechnology, particularly in the development of agents targeting tetraspanin 33.

Latest Patents

Moyron-Quiroz holds a patent for "Anti-tetraspanin 33 agents and compositions and methods for making and using the same." This patent describes compositions and methods for creating and utilizing anti-TSPAN33 agents, including monoclonal antibodies and TSPAN33-binding antibody fragments.

Career Highlights

He is currently associated with BioLegend, Inc., a company known for its innovative products in the life sciences sector. His work focuses on advancing therapeutic options through the development of novel antibody-based solutions.

Collaborations

Moyron-Quiroz collaborates with Takatoku Oida, contributing to the advancement of research in their field.

Conclusion

Juan E Moyron-Quiroz is a key figure in the biotechnology industry, with a focus on anti-tetraspanin research that holds promise for future therapeutic applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…